Jerusalem Pharmaceuticals, a leading publicly listed company in Palestine (PEX:JPH), with manufacturing facilities in three countries and sales operations in three continents, is pleased to confirm a partnership with the Islamic Reporting Initiative (IRI).
“At Jerusalem Pharmaceuticals, we are pleased to announce a partnership with the Islamic Reporting Initiative”, says Dr Iyad Masrouji, CEO of Jerusalem Pharmaceuticals.
“The pharmaceutical industry is, by virtue, one that is intent on delivering solutions. Jerusalem Pharmaceuticals manufactures a range of products within the field of health, and so health and well-being is at the core of what we do. The IRI framework recognises the importance of health and well-being – at the individual, organizational, and national level – and so it is of great interest to us and one that we are pleased to support”.
“We, at Jerusalem Pharmaceuticals, are fortunate enough to be in a position of growth. We are looking to expand into new markets, and demonstrating our compliance to international standards of best practice is paramount to our current and future achievements”.
“We have previously undertaken CSR and Sustainability reporting to evaluate our own progress in quality and environment management. From this process, we recognise that as an international business, we have extensive capacity to generate real impact as part of our CSR programs – both internally and externally – and we seek to maximise this potential. The IRI framework aspires to facilitate this; to ensure that our CSR program is mutually beneficial and complementary to business, community, and environment needs”.
“The greatest challenges that we, and many other corporations, experience include gaining sufficient buy-in from all stakeholders, and ensuring that a CSR strategy is complementary to the demands of the business and its local environment. Overcoming these challenges serves to ensure that CSR has a meaningful, tangible, and long-lasting impact”.
“As a partner, we intend to contribute this insight to the development of the IRI. As such, we hope to make a lasting impression in the way CSR reporting will be conducted in the future, to form a tool that facilitates prosperous conditions for all”.
“We invite other corporations to join us in this venture, to contribute to the development of the IRI to make the future of CSR reporting more purposeful and meaningful”.
For more informations please visit: http://www.jepharm.ps
For more information on becoming a partner with the Islamic Reporting Initiative, please contact email@example.com or visit our website at www.islamicreporting.org. For more information on Jerusalem Pharmaceuticals